Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033176 · ClinicalTrials.gov registry record · Phase 2
Immune Restoration by Lipoic Acid in AIDS
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00033176 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 33 participants.
The verdict
NCT00033176, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immunomodulatory and antiviral effects of the glutathione-restoring dithiol, alpha lipoic acid (ALA) in HIV-infected persons unresponsive to highly active antiretroviral treatment (HAART).
Interventions
- DRUG Alpha Lipoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2002-02 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033176
The ClinicalTrials.gov registry entry for NCT00033176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha Lipoic Acid is the first listed.
NCT00033176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033176 about?
NCT00033176 is a clinical study titled "Immune Restoration by Lipoic Acid in AIDS". The purpose of this study is to determine the immunomodulatory and antiviral effects of the glutathione-restoring dithiol, alpha lipoic acid (ALA) in HIV-infected persons unresponsive to highly active antiretroviral treatment (HAART).
What is the current status of trial NCT00033176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2002-02. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00033176?
The interventions under investigation include: Alpha Lipoic Acid (DRUG).
Who is sponsoring clinical trial NCT00033176?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.